Article
Neurological toxicity after phenytoin infusion in a pediatric patient with epilepsy: influence of CYP2C9, CYP2C19 and ABCB1 genetic polymorphisms.
The pharmacogenomics journal - 1 Aug 2013
Dorado P, López-Torres E, Peñas-Lledó E M, Martínez-Antón J, Llerena A
Abstract excerpt
Pharmacogenetic studies have shown that genetic defects in drug-metabolizing enzymes encoded by CYP2C9, CYP2C19 genes and by the transporter ABCB1 gene can influence phenytoin (PTH) plasma levels and toxicity. The patient reported here is a 2-year-old girl with a medical history of cryptogenic (probably symptomatic) epilepsy, who had her first focal seizure with secondary generalization at 13 months of age. She...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
